Head-to-head GEFAL study confirms non-inferiority of bevacizumab

PARIS — A prospective, multicenter, randomized, double-masked study carried out in France proved the non-inferiority of bevacizumab to ranibizumab, confirming the previous finding of the CATT and other European head-to-head comparison studies. The GEFAL (Groupe d’Evaluation Français Avastin versus Lucentis) study involved 46 hospitals and private clinics. It was an independent study financed with €4 million from the government and national insurance fund.

Full Story →